Burning Rock Biotech, a company focusing on the application of next generation sequencing technology in precision oncology, announced that it has applied to trade on the main market of the London Stock Exchange by way of a direct listing.
Burning Rock has prepared a registration document in connection with the direct listing, which has been approved by the Financial Conduct Authority. The company’s American depositary shares trade on the Nasdaq and, if the direct listing is completed, would likewise trade on the London Exchange.
Publicly available information thus far submitted by the company to the FCA does not disclose how much Burning Rock hopes to raise in any direct listing. Read more.
